|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 327.05 CHF | +0.02% |
|
-2.27% | -0.27% |
| 03:27pm | Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns | MT |
| 11:10am | Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy | MT |
Main competitors
| Capi.($) | Investor | ESG MSCI | Fundamentals | Financial revisions | Global Valuation | Visibility | Consensus | ||
|---|---|---|---|---|---|---|---|---|---|
| 32TCr | AA | ||||||||
| 1,02800Cr | A | ||||||||
| 61TCr | BBB | ||||||||
| 43TCr | AA | - | |||||||
| 28TCr | AAA | ||||||||
| 26TCr | A | ||||||||
| 22TCr | A | ||||||||
| 19TCr | A | ||||||||
| 16TCr | AA | ||||||||
| 14TCr | A | ||||||||
| 12TCr | AA | ||||||||
| 12TCr | A | ||||||||
| 10TCr | AA | ||||||||
| 10TCr | AA | ||||||||
| 7.36TCr | AA | ||||||||
| 5.52TCr | AA | ||||||||
| 5.34TCr | AA | ||||||||
| 5.2TCr | AA | ||||||||
| 4.25TCr | AA | ||||||||
| 3.76TCr | AA | ||||||||
| Average | 21.97TCr | AA | |||||||
| Weighted average by Cap. | AA |
- Stock Market
- Stocks
- ROP Stock
- Sector Roche Holding AG
- Sector ratings
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















